HK Stock MarketDetailed Quotes
01513 LIVZON PHARMA
- 26.350
- +0.550+2.13%
Not Open Apr 25 16:09 CST
24.43BMarket Cap11.19P/E (TTM)
26.450High25.500Low959.40KVolume25.500Open25.800Pre Close25.13MTurnover0.31%Turnover Ratio11.33P/E (Static)927.23MShares29.05052wk High1.52P/B8.16BFloat Cap21.50052wk Low1.76Dividend TTM309.83MShs Float37.839Historical High1.760Dividend LFY3.68%Amplitude3.028Historical Low26.196Avg Price100Lot Size6.68%Div YieldTTM6.68%Div Yield LFY
LIVZON PHARMA Key Stats
All
YOY
| (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -4.99%3.24B | -1.58%12.43B | 1.76%9.65B | 6.15%6.69B | -1.90%3.41B | 4.69%12.63B | 1.27%9.49B | 1.08%6.3B | 3.86%3.48B | 14.67%12.06B |
| Operating income | -4.99%3.24B | -1.58%12.43B | 1.76%9.65B | 6.15%6.69B | -1.90%3.41B | 4.69%12.63B | 1.27%9.49B | 1.08%6.3B | 3.86%3.48B | 14.67%12.06B |
| Operating expenses | 9.10%-1.15B | -0.09%-4.47B | -6.42%-3.48B | -9.61%-2.4B | -7.03%-1.26B | -4.90%-4.46B | -2.16%-3.27B | -3.14%-2.19B | -4.88%-1.18B | -15.77%-4.25B |
| Gross profit | -2.58%2.1B | -2.49%7.96B | -0.70%6.17B | 4.30%4.29B | -6.46%2.15B | 4.58%8.17B | 0.81%6.22B | 0.01%4.11B | 3.34%2.3B | 14.08%7.81B |
| Selling expenses | 9.20%-876.11M | 7.44%-3.6B | 3.03%-2.81B | -3.35%-1.97B | 12.80%-964.91M | -0.09%-3.89B | 5.97%-2.9B | 6.92%-1.9B | 2.50%-1.11B | -26.27%-3.88B |
| Administrative expenses | -28.75%-192.68M | 0.39%-654.27M | 12.23%-486.96M | 12.38%-310.93M | 24.94%-149.65M | 1.10%-656.86M | -13.81%-554.79M | -22.34%-354.87M | -16.94%-199.38M | 0.02%-664.18M |
| Research and development expenses | 23.52%-238.17M | 6.44%-1.33B | -0.72%-985.76M | -10.15%-610.78M | -8.00%-311.41M | -24.51%-1.43B | -24.48%-978.75M | -9.40%-554.52M | -24.56%-288.33M | -29.59%-1.15B |
| Profit from asset sales | --306.57K | -119.80%-170.44K | -117.81%-199.73K | 35.71%-328.23K | ---- | -87.77%860.66K | 18.83%1.12M | -260.99%-510.52K | -1,788.99%-370.36K | 755.98%7.03M |
| Revaluation surplus | 105.96%1.55M | 65.92%-25.65M | 46.35%-41.99M | 63.45%-32.45M | 51.49%-25.95M | -226.89%-75.27M | -383.80%-78.27M | -355.14%-88.78M | -46.06%-53.5M | -361.47%-23.03M |
| -Changes in the fair value of other assets | 105.96%1.55M | 65.92%-25.65M | 46.35%-41.99M | 63.45%-32.45M | 51.49%-25.95M | -226.89%-75.27M | -383.80%-78.27M | -355.14%-88.78M | -46.06%-53.5M | -361.47%-23.03M |
| Impairment and provision | 15.15%-9.74M | -164.17%-323.1M | 2.09%-126.95M | -72.01%-52.76M | -154.10%-11.48M | -90.17%-122.31M | -188.35%-129.66M | 17.53%-30.67M | 82.62%-4.52M | 12.56%-64.31M |
| -Other impairment is provision | 15.15%-9.74M | -164.17%-323.1M | 2.09%-126.95M | -72.01%-52.76M | -154.10%-11.48M | -90.17%-122.31M | -188.35%-129.66M | 17.53%-30.67M | 82.62%-4.52M | 12.56%-64.31M |
| Special items of operating profit | -45.08%44.37M | 17.21%266.6M | 12.19%169.85M | 28.50%153.02M | 8.80%80.8M | -23.59%227.46M | -28.92%151.39M | -21.57%119.08M | -17.46%74.26M | -18.18%297.67M |
| Operating profit | 8.89%794.38M | 2.97%2.14B | 9.41%1.77B | 12.80%1.39B | 6.41%729.54M | -5.24%2.08B | -12.55%1.62B | -8.72%1.23B | 1.26%685.57M | -8.34%2.2B |
| Financing cost | 522.72%54.51M | 1.02%271.5M | -14.83%216.48M | -56.60%41.45M | -76.92%8.75M | 283.72%268.76M | 946.30%254.17M | 281.83%95.51M | 62.53%37.93M | -32.42%70.04M |
| Special items of earning before tax | -55.83%-4.45M | -62.17%-32.44M | -152.29%-17.13M | -96.25%-5.06M | -1,081.96%-2.85M | 6.08%-20.01M | -2.91%-6.79M | -178.18%-2.58M | -91.65%290.56K | -93.41%-21.3M |
| Earning before tax | 14.82%844.44M | 2.24%2.38B | 5.59%1.97B | 7.62%1.42B | 1.61%735.44M | 3.78%2.33B | -0.13%1.87B | -3.54%1.32B | 2.83%723.79M | -9.79%2.25B |
| Tax | -5.58%-128.36M | -29.36%-485.07M | -13.19%-345.79M | -21.57%-249.3M | -7.91%-121.58M | -27.72%-374.97M | -19.42%-305.49M | -7.15%-205.07M | -6.19%-112.67M | 18.02%-293.59M |
| After-tax profit from continuing operations | 16.65%716.08M | -2.96%1.9B | 4.10%1.62B | 5.06%1.17B | 0.45%613.86M | 0.18%1.96B | -3.24%1.56B | -5.28%1.12B | 2.24%611.12M | -8.41%1.95B |
| Earning after tax | 16.65%716.08M | -2.96%1.9B | 4.10%1.62B | 5.06%1.17B | 0.45%613.86M | 0.18%1.96B | -3.24%1.56B | -5.28%1.12B | 2.24%611.12M | -8.41%1.95B |
| Minority profit | 238.80%108.26M | -221.40%-56.05M | -57.47%22.77M | -60.48%39.5M | -44.75%31.95M | -73.83%46.17M | -66.50%53.53M | -14.79%99.96M | -25.96%57.83M | -57.63%176.42M |
| Profit attributable to shareholders | 4.45%607.82M | 2.32%1.95B | 6.29%1.6B | 11.50%1.13B | 5.17%581.91M | 7.53%1.91B | 3.72%1.51B | -4.23%1.02B | 6.47%553.29M | 3.54%1.78B |
| Basic earnings per share | 4.84%0.65 | 2.94%2.1 | 6.83%1.72 | 11.93%1.22 | 5.08%0.62 | 7.37%2.04 | 3.87%1.61 | -4.39%1.09 | 5.36%0.59 | 3.83%1.9 |
| Diluted earnings per share | 4.84%0.65 | 2.94%2.1 | 6.83%1.72 | 11.93%1.22 | 5.08%0.62 | 7.37%2.04 | 3.87%1.61 | -4.39%1.09 | 7.27%0.59 | 3.83%1.9 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | Grant Tung Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Tung Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Tung Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg